Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor‐negative and HER2‐positive breast cancer?

Eitemau Tebyg

• T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes
  gan: Wang, Changjun, et al.
  Cyhoeddwyd: (2021)
• Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value
  gan: Wang, Changjun, et al.
  Cyhoeddwyd: (2020)
• Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
  gan: Changjun Wang, et al.
  Cyhoeddwyd: (2020-07-01)
• Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
  gan: Wang, Changjun, et al.
  Cyhoeddwyd: (2020)
• The impact of pre-existed and SERM-induced non-alcoholic fatty liver disease on breast cancer survival: a meta-analysis
  gan: Wang, Changjun, et al.
  Cyhoeddwyd: (2020)